FTAC Olympus stock surges after Payoneer merger talks reportedPayoneer Inc., an online payments specialist, is in talks to go public through a merger with FTAC Olympus Acquisition Corp., a blank-check firm, according to people with knowledge of the matter.
The special purpose acquisition company has begun talks to raise new equity to support a transaction that’s slated to value the combined entity at more than $2.5 billion, said one of the people, who asked to not be identified because the matter isn’t public. As a deal isn’t finalized, it’s possible terms change or talks fall apart.
Representatives for New York-based Payoneer and FTAC declined to comment.
Founded in 2005, Payoneer -- which has said it’s profitable -- is backed by investors including Wellington Management Co., TCV, Greylock Partners, Ping An and Viola Ventures. The company, founded in Israel by Yuval Tal and now led by Chief Executive Officer Scott Galit, operates in more than 200 countries and territories. It provides services including cross-border payments for customers including Airbnb Inc., Amazon.com Inc., Google and Walmart Inc. its website shows.
FTAC, led by Chairman Betsy Cohen and Chief Executive Officer Ryan Gilbert, raised roughly $755 million in an August initial public offering for the purpose of acquiring or merging with a technology or financial services technology-focused company.
Read More: SoFi Plans for More Mergers After Going Public Through SPAC
Cohen is also chairman of blank-check firms FinTech Acquisition Corp. IV, which last month agreed to combine with Perella Weinberg Partners, and FinTech Acquisition Corp. V. She’s also chairman of FTAC Athena Acquisition Corp. which this week filed paperwork ahead of a targeted $220 million IPO and was the chairman of FinTech Acquisition Corp. III when it merged with payments company Paya Holdings Inc.
www.reddit.com
Stockstrading
VANGUARD just invested with 2.6 mil sharesInuvo Prices $8.0 Million Common Stock Offering
has entered into a securities purchase agreement with institutional investors for the purchase and sale of 13,333,334 shares of its common stock, par value $0.001 per share, at a price of $0.60 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be $8.0 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 19, 2021, subject to the satisfaction of customary closing conditions.
finance.yahoo.com
Possible big move for Microsoft coming. $MSFTPossible big move for Microsoft coming. $MSFT. Has been trading in this wedge formation, now with big rally on January 20, 2021, possible of breakout with major upside. NASDAQ:MSFT
Hormel Foods Corp. $HRL - investment idea 💡 This idea is based on my technical analysis only.
Do your research and trade on your own risk!
GigCapital2 Has Entered Into Business Combination AgreementsGigCapital2 Has Entered Into Business Combination Agreements With UpHealth and Cloudbreak to Form Combined Company to List on the NYSE, Creating a Unified and Profitable Global Digital Health Company
In 2021, UpHealth is expected to generate over $190M in revenue and $24M in EBITDA; 69% of the 2021 incremental revenue growth is already contracted.
UpHealth will be positioned for predictable growth and profitability enabling substantial reinvestment opportunities.
Pro forma enterprise value is approximately $1.35 billion.
UpHealth will be a leading global digital healthcare company serving an entire spectrum of healthcare needs and will be established in fast growing sectors of the digital health industry.
The Global Telehealth Platform will consist of a U.S. division and an international division that, together, are anticipated to grow revenues by an additional $47 million in 2021.
The U.S. division of Global Telehealth following the combination, Cloudbreak, is a leading unified telemedicine platform performing more than 100,000 encounters per month on over 14,000 video endpoints at over 1,800 healthcare venues nationwide.
Digital Pharmacy - MedQuest Pharmacy ("MedQuest") is a leading full-service manufactured and compounded pharmacy licensed in all 50 states that pre-packages and ships medications direct to patients. MedQuest serves an established network of 13,000 providers.
UpHealth will have agreements to deliver digital healthcare in more than 10 countries globally. These various companies are expected to generate approximately $115 million in revenue and over $13 million of EBITDA in 2020 and following the combination, UpHealth expects to generate over $190 million in revenue and $24 million in EBITDA in 2021.
The proposed business combinations are expected to be completed in Q1 2021
finance.yahoo.com
Twitter looking to resume the uptrendIn my previous post, I've mentioned that there is a correction coming for Twitter and that was catalyzed after the social platform banned Trump's account.
Price has landed perfectly on the uptrend major support and formed yesterday a nicely looking pinbar.
RIS has turned from oversold zone and if you are more aggressive current price is tempting enough to enter long. I would wait for the additional confirmation from MACD. My long-term target is $58 if bullish conditions are confirmed.
Keep eyes on Boeing - a lot of room for a promising recoveryIt took some time for Boeing to break out of its bullish wedge, but the support held well, and we see some more stubborn attempts from buyers to push the price up.
RSI is rising above 50, MACD has crossed over and the histogram is moving slowly towards positive territory. Earnings are after 7 days. so keep that in mind. An impulse above $216 will confirm the continuation of the bullish trend. My long term target is $250.
What's in for Bank of America after the earnings report?Today we saw the earnings report for Bank of America and it did not meet the investor's expectations. So far the earnings season (for the banks) starts a bit off. The EPS came above expectations at 0.59 versus 0.54 expected. Revenue though came in with a miss - 20.1B against 20.56B expected. The main cause for the miss cited is the COVID-19 pandemic.
RSI is already crossing from overbought territory, though MACD's crossing is lagging. The histogram is showing a divergence with the price which is in line with RSI's early divergence with the price.
My expectations are for a drop towards the trend line support at the $31.35 zone. A breach there may lead to a potential drop towards $30.61 and by this jeopardizing the uptrend.
Oppenheimer Analyst Says buy, following of some positive dataOppenheimer 5-star Analyst Says BioNano Genomics is ready to Execute in 2021.
the latest move was decidedly upbeat. In Wednesday’s session, the stock took off to the tune of 40% following the publication of some positive data.
article which made side-by-side comparisons between Bionano’s optical genome mapping platform Saphyr and PacBio's HiFi chemistry revealed that Saphyr had the upper hand on several metrics.
Across 32 different human genomes, PacBio technologies found only 72% of the large SVs (structural variants) that Bionano’s optical genome mapping (OGM) detected.
Saphyr was also found to be better at locating indels in regions correlated to neurodevelopment.
Additionally, Saphyr appears to be more cost effective. The platform’s estimated cost of $500 per genome coming in far below the $10,000-20,000 per genome when HiFi and SMRT sequencing are put into action.
Oppenheimer’s Kevin DeGeeter believes the data should help Saphyr make further inroads in the “large SV research market.” The analyst views 2021 “largely as an execution year.”
We expect the data to support broader adoption of Saphyr for de novo sequencing and research applications. the 5-star analyst said.
“Furthermore, we expect 2021 to be an important year for adoption of Saphyr for clinical cytogenetics market based on a series of positive recent publications... Based on our current assessment of the competitive landscape, we do not believe long-read sequencing technologies can replicate Saphyr's performance and cost structure for digital cytogenetics testing.”
Accordingly, DeGeeter reiterated an Outperform (i.e. Buy) on BNGO shares, along with a $1.5 price target. The implication for investors? Strong upside of 113% .
Two other analysts have thrown the hat in with a BNGO review recently, one saying Buy and the other recommending a Hold -- all add up to a Moderate Buy consensus rating. Meanwhile, the average price target stands at $1.42, implying gains of 101% could be in the cards over the next 12 months.
finance.yahoo.com
Disney's price on a crossroadHolidays are over and it is time to get back into the markets, refreshed and with new strength.
I am making another revision of Disney as the price on Friday closed at the internal trend support and played out the small bearish flag. Volumes were higher than Thursday as there were 12.23M shares traded against 8.951M shares on the day before Friday. The activity had increased before the weekends, but with that dip buying before the close, it looked more like long position covering.
Now two options are on the table that will be crucial if confirmed by the price action.
1. Price dips inside the $165 - $169 zone and we may see potential trend-reversing price action;
2. The zone holds and Disney'sprice resumes inside the uptrend with the broader market;
Be cautious on the first trading day after the break.
CALM Technical Analysis 🧙Cal-Maine Foods Inc produces and sells shell eggs. Its main market is United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and foodservice distributors. The company's brands are: Egg-Land's Best, Land O' Lakes, Farmhouse, and 4-Grain
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
BMA Technical Analysis 🧙Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The firm generates most of its revenue from Argentina.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
TTNP Technical Analysis 🧙 Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. The company product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
buy VISA 11/1/2021Visa is moving in a short-term uptrend
The stock is testing the moving average of 13
So you can buy a target of 229.8, stop losses, 204.16
DBV Technologies rally on Positive FDA CommunicationDBV Technologies Spikes on Positive FDA Communication
DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment.
The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in connection with its biologics license application (BLA) for Viaskin Peanut DBV712, its once-daily epicutaneous patch to treat peanut allergy in children ages four to 11.
"We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided," said Daniel Tassé, CEO of DBV Technologies. “We look forward to working with our investigators, clinical trial sites, and key stakeholders as we continue in our development of investigational Viaskin Peanut."
DBV says it will address details about a new human factor validation study and additional chemistry, manufacturing and controls data in subsequent communication with the FDA.
"We intend to advance a remediation plan for Viaskin Peanut and work closely with FDA to review protocols and re-file our BLA as soon as possible, so that we can bring Viaskin Peanut, if approved, to patients suffering from peanut allergies," Tassé said.
www.thestreet.com
finance.yahoo.com
BlackBerry sold 90 smartphone technology patents to HuaweiShares of BlackBerry (NYSE:BB) soared Thursday despite an apparent lack of company-specific news. Investors may have been responding to a report published earlier this week that said the company sold some of its patents to Huawei.
Canadian newspaper The Globe and Mail reported Tuesday that BlackBerry had sold 90 smartphone technology patents to the Chinese technology giant Huawei.
BlackBerry stopped manufacturing smartphones back in 2016, but the company still has a large number of patents relating to those devices. Selling some of them is yet another clear sign that it has moved on and is putting its efforts into other businesses.
investors may be continuing to express their positive sentiment toward the tech stock, which is up more than 100% over the past six months.
www.fool.com
Full Commercial Launch of Tigereye(TM) Image-Guided CTO CrossingAvinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter
With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.
During the fourth quarter of 2020, Avinger conducted a limited launch at 12 clinical centers in the U.S. and Germany. Approximately 50 CTO cases were successfully performed, showcasing Tigereye's advanced clinical capabilities and excellent product reliability in a variety of lesion types and settings.
The limited launch program demonstrated Tigereye's strong clinical results and efficiency across a wide range of PAD cases
"We believe full commercial availability of the Tigereye device will be an important contributor to expanding our revenue growth opportunities in 2021, both in terms of attracting new Avinger user sites and supporting higher utilization per site,"
finance.yahoo.com
Mcewen Mining Inc $MUX - investment idea 💡 Be careful, multiple entries selected so hope you have a strong risk management strategy.
This idea is based on my technical analysis only.
Do your research and trade on your own risk!
Sale of Manufacturing Operations and Global Supply AgreementAcorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into "At The Market" Offering Agreement
$80 million up-front payment will substantially increase cash balance
Sale, restructuring and other operating expense reductions will reduce annual operating expenses by approximately $40 million
Total 2021 non-GAAP operating expense guidance expected to be $130-$140 million1
At The Market (ATM) offering allows the sale of common stock at aggregate value up to $15.25 million
Supply agreement will ensure uninterrupted supply of INBRIJA (levodopa inhalation powder) to people with Parkinson’s
finance.yahoo.com stock
Biomerica’s Covid-19 Antigen Rapid Test Receives CE MarkBiomerica’s Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark
Biomerica receives first orders and plans to ship tests in coming weeks
Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR tests
The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US.
merica’s new COVID-19 Antigen Rapid Test is highly portable, affordable, and provides results in 15 minutes with no equipment required to perform or read the test.
finance.yahoo.com
Avangrid $AGR - investment idea 💡 This idea is based on my technical analysis only.
Do your research and trade on your own risk!
CCIV surge on news of plans to take Lucid Motors public via SPACChurchill Capital Corp IV extends 2-day surge to over 50% on news of plans to take Lucid Motors public via SPAC
Shares of Churchill Capital Corp. IV are up over 50% in a two-day streak to start the week.
News of the SPAC potentially taking EV company Lucid Motors public is driving the share price higher.
The fourth of seven 'blank-check' companies operated by Michael Klein, Churchill Capital Corp. IV's plan for Lucid Motors would keep the SPAC craze going in 2021.
the partner firm is Lucid Motors, a relatively well-established EV manufacturer based out of Newark, California, and which targets the luxury end of the car market. The deal could potentially value Lucid at $15 billion, according to Bloomberg.
markets.businessinsider.com
GameStop (GME) Falls At Heavy Resistance - Squeeze or Dump?Just posting this chart by request. I've been following GameStop for a while. Michael Burry bought a large position over the past year, yet price continued to head to new lows. Meanwhile, a trader I know made an observation of share price's reaction to major console releases. I was a bit skeptical of the bullish argument at first, but clearly it turned out to be correct in the medium term. I will explain why, a little further down.
This chart shows some important trend lines. I'm using the monthly chart because GME has a relatively long price history, and the 50 Month MA (red) seems rather important. The trendlines in this chart I actually drew many months ago. One of them served as resistance on the recent move.
If GME can head back up this week and sustain above that first teal trendline and the 50 month MA, there is the possibility of an enormous short squeeze. On the other hand, if price rolls back below the first red downtrend line, it can easily dump back to the lows.
This isn't an attempt to predict where price will go next, but just to outline the structure of this stock. In the broader picture, video games have actually gone up in demand over the last year. With much of life being relegated to the home, entertainment has become even more vital. Retro games are also selling at much higher prices than before the pandemic. Especially if fiscal policy continues to favor a weakening dollar, we can see some fairly ridiculous price action on equities for a little while until an inevitable bubble pop. For GME, if price breaks and holds the $13-14 resistance again, we can see $29-30 fairly quickly. If it breaks above all my downtrends, it can even reach a new all-time-high, as ridiculous as that sounds. This is not financial advice! This is for education, entertainment, and speculation only.
-Victor Cobra
